247 related articles for article (PubMed ID: 32350988)
1. Accurate quantification of urinary metabolites for predictive models manifest clinicopathology of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Shimada S; Morozumi K; Sato M; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
Cancer Sci; 2020 Jul; 111(7):2570-2578. PubMed ID: 32350988
[TBL] [Abstract][Full Text] [Related]
2. Predictive model for recurrence of renal cell carcinoma by comparing pre- and postoperative urinary metabolite concentrations.
Morozumi K; Kawasaki Y; Maekawa M; Takasaki S; Sato T; Shimada S; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
Cancer Sci; 2022 Jan; 113(1):182-194. PubMed ID: 34710258
[TBL] [Abstract][Full Text] [Related]
3. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
[TBL] [Abstract][Full Text] [Related]
4. Searching for prognostic biomarkers for small renal masses in the urinary proteome.
Di Meo A; Batruch I; Brown MD; Yang C; Finelli A; Jewett MA; Diamandis EP; Yousef GM
Int J Cancer; 2020 Apr; 146(8):2315-2325. PubMed ID: 31465112
[TBL] [Abstract][Full Text] [Related]
5. Detection of urinary miRNAs for diagnosis of clear cell renal cell carcinoma.
Cochetti G; Cari L; Nocentini G; Maulà V; Suvieri C; Cagnani R; Rossi De Vermandois JA; Mearini E
Sci Rep; 2020 Dec; 10(1):21290. PubMed ID: 33277569
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Footprinting of a Clear Cell Renal Cell Carcinoma in Vitro Model for Human Kidney Cancer Detection.
Knott ME; Manzi M; Zabalegui N; Salazar MO; Puricelli LI; Monge ME
J Proteome Res; 2018 Nov; 17(11):3877-3888. PubMed ID: 30260228
[TBL] [Abstract][Full Text] [Related]
7. ARCHITECT® urine-neutrophil gelatinase-associated lipocalin (u-NGAL) assay as new prognostic marker for clear cell Renal Cell Carcinoma (ccRCC) (preliminary results).
Ben Khadhra H; Rose-Robert F; Herpe YE; Sevestre H; Choukroun G; Catherine L; Amant C; Saint F
Int Urol Nephrol; 2021 Jan; 53(1):59-67. PubMed ID: 32783115
[TBL] [Abstract][Full Text] [Related]
8. Detection of urinary cell-free miR-210 as a potential tool of liquid biopsy for clear cell renal cell carcinoma.
Li G; Zhao A; Péoch M; Cottier M; Mottet N
Urol Oncol; 2017 May; 35(5):294-299. PubMed ID: 28089386
[TBL] [Abstract][Full Text] [Related]
9. miR-144-3p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma.
Lou N; Ruan AM; Qiu B; Bao L; Xu YC; Zhao Y; Sun RL; Zhang ST; Xu GH; Ruan HL; Yuan CF; Han WW; Shi HC; Yang HM; Zhang XP
Urol Oncol; 2017 Jan; 35(1):36.e7-36.e14. PubMed ID: 27633984
[TBL] [Abstract][Full Text] [Related]
10. Urinary RKIP/p-RKIP is a potential diagnostic and prognostic marker of clear cell renal cell carcinoma.
Papale M; Vocino G; Lucarelli G; Rutigliano M; Gigante M; Rocchetti MT; Pesce F; Sanguedolce F; Bufo P; Battaglia M; Stallone G; Grandaliano G; Carrieri G; Gesualdo L; Ranieri E
Oncotarget; 2017 Jun; 8(25):40412-40424. PubMed ID: 28418894
[TBL] [Abstract][Full Text] [Related]
11. Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma.
Sandim V; Pereira Dde A; Kalume DE; Oliveira-Carvalho AL; Ornellas AA; Soares MR; Alves G; Zingali RB
Urol Oncol; 2016 Jan; 34(1):5.e11-25. PubMed ID: 26420021
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study.
Morrissey JJ; Mellnick VM; Luo J; Siegel MJ; Figenshau RS; Bhayani S; Kharasch ED
JAMA Oncol; 2015 May; 1(2):204-12. PubMed ID: 26181025
[TBL] [Abstract][Full Text] [Related]
13. Urine metabolomics analysis for kidney cancer detection and biomarker discovery.
Kim K; Aronov P; Zakharkin SO; Anderson D; Perroud B; Thompson IM; Weiss RH
Mol Cell Proteomics; 2009 Mar; 8(3):558-70. PubMed ID: 19008263
[TBL] [Abstract][Full Text] [Related]
14. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
[TBL] [Abstract][Full Text] [Related]
15. The predictive and prognostic values of serum amino acid levels for clear cell renal cell carcinoma.
Zhang F; Ma X; Li H; Guo G; Li P; Li H; Gu L; Li X; Chen L; Zhang X
Urol Oncol; 2017 Jun; 35(6):392-400. PubMed ID: 28188089
[TBL] [Abstract][Full Text] [Related]
16. Identification of dysregulated serum miR-508-3p and miR-885-5p as potential diagnostic biomarkers of clear cell renal carcinoma.
Liu S; Deng X; Zhang J
Mol Med Rep; 2019 Dec; 20(6):5075-5083. PubMed ID: 31661117
[TBL] [Abstract][Full Text] [Related]
17. Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA.
Nizioł J; Bonifay V; Ossoliński K; Ossoliński T; Ossolińska A; Sunner J; Beech I; Arendowski A; Ruman T
Anal Bioanal Chem; 2018 Jun; 410(16):3859-3869. PubMed ID: 29658093
[TBL] [Abstract][Full Text] [Related]
18. Exploring serum metabolic markers for the discrimination of ccRCC from renal angiomyolipoma by metabolomics.
Xiang M; Du F; Dai J; Chen L; Geng R; Huang H; Xie B
Biomark Med; 2020 Jun; 14(8):675-682. PubMed ID: 32613842
[No Abstract] [Full Text] [Related]
19. MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma.
Mytsyk Y; Dosenko V; Borys Y; Kucher A; Gazdikova K; Busselberg D; Caprnda M; Kruzliak P; Farooqi AA; Lubov M
Int Urol Nephrol; 2018 May; 50(5):851-859. PubMed ID: 29549624
[TBL] [Abstract][Full Text] [Related]
20. Cell-free RNA content in urine as a possible molecular diagnostic tool for clear cell renal cell carcinoma.
Zhao A; Péoc'h M; Cottier M; Genin C; Mottet N; Li G
Int J Cancer; 2015 Jun; 136(11):2610-5. PubMed ID: 25379634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
